2-chloro-5-[3-(dimethylaminomethyl)pyrrolidin-1-yl]-N-[(6-methylsulfonyl-1,3-benzothiazol-2-yl)carbamoyl]benzamide | 1143024-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-chloro-5-[3-(dimethylaminomethyl)pyrrolidin-1-yl]-N-[(6-methylsulfonyl-1,3-benzothiazol-2-yl)carbamoyl]benzamide
• 英文别名: 2-chloro-5-[3-[(dimethylamino)methyl]pyrrolidin-1-yl]-N-[(6-methylsulfonyl-1,3-benzothiazol-2-yl)carbamoyl]benzamide
• CAS: 1143024-48-9
• 化学式: C₂₃H₂₆ClN₅O₄S₂
• 分子量: 536.076
• InChiKey: UGSQSGNVVFBFDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  148
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• [EN] BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS<br/>[FR] AGENTS THÉRAPEUTIQUES - 802
  申请人：ASTRAZENECA AB

  公开号：WO2009047558A1

  公开（公告）日：2009-04-16

  A compound of formula (I) or a pharmaceutically acceptable salt thereof in which R1, R2 , R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.

  化合物的分子式（I）或其药用盐，其中R1、R2、R3、R4和m如说明书中所述，用于治疗肥胖和/或糖尿病。
• THERAPEUTIC AGENTS
  申请人：ALLEN Jack McQueen

  公开号：US20120115845A1

  公开（公告）日：2012-05-10

  A compound of formula I or a pharmaceutically acceptable salt thereof in which R 1 , R 2 , R 3 , R 4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.

  公式I的化合物或其药学上可接受的盐，其中R1、R2、R3、R4和m如说明书所述，用于治疗肥胖症和/或糖尿病。
• BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS
  申请人：Allen Jack McQueen

  公开号：US20110124621A1

  公开（公告）日：2011-05-26

  A compound of formula I or a pharmaceutically acceptable salt thereof in which R 1 , R 2 , R 3 , R 4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.

  化合物I的式或其药学上可接受的盐，其中R1、R2、R3、R4和m如规范所述，用于治疗肥胖和/或糖尿病。
• Therapeutic Agents - 802
  申请人：ALLEN Jack McQueen

  公开号：US20090186870A1

  公开（公告）日：2009-07-23

  A compound of formula I or a pharmaceutically acceptable salt thereof in which R 1 , R 2 , R 3 , R 4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.

  化合物I的公式或其药学上可接受的盐，其中R1、R2、R3、R4和m如规范所述，用于治疗肥胖和/或糖尿病。
• BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS
  申请人：Astrazeneca AB

  公开号：EP2607357A1

  公开（公告）日：2013-06-26

  A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.

  式 I 的化合物 或其药学上可接受的盐，其中 R1、R2、R3、R4 和 m 如说明书所述，用于治疗肥胖症和/或糖尿病。